SXTP Stock Forecast & Price Target

60 Degrees is well positioned because it is simultaneously expanding ARAKODA’s commercial reach and building a pipeline with multiple shots on goal. The February GoodRx launch, the April Runway Health partnership, and savings of up to 30% should support broader pre-departure access, while the tafenoquine babesiosis program has shown encouraging clinical evidence, with all three enrolled patients cured after completing the regimen. In addition, the Q1 option with Florida State University to pursue exclusive licensing for castanospermine extraction from Australian Chestnut seeds adds a non-Rx dietary supplement opportunity that could diversify future revenue streams.

60 Degrees is under pressure from weak commercial execution, with Q1 FY26 product revenue of only $162,000 versus a $300,000-$400,000 run-rate in 2H25, as higher returns and softer ARAKODA sell-through drove US unit sales down 19% year-over-year to 1,276 boxes. The company also posted a $2.2 million net loss on $0.2 million of sales, while operating expenses of $2.2 million and an annual burn rate of roughly $8 million underscore an unsustainable cost structure relative to its small revenue base. Although it raised about $3.4 million net through ATM sales and ended the quarter with $3.3 million in cash, the need for continued equity financing, potential dilution, and limited visibility into its babesiosis and other pipeline programs create substantial fundamental risk.